Sign In
Buy NUVA
$39.75
+0 (+0%)
At Close: Nov 30, 2023
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
NuVasive Expands Advanced Materials Science™ Implant Portfolio to Additional Thoracolumbar Procedures
12:33pm, Tuesday, 05'th May 2020
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expans
NuVasive to Participate in BofA Securities 2020 Healthcare Conference
08:03pm, Monday, 04'th May 2020
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that manag
JP Morgan Maintains Neutral on NuVasive, Lowers Price Target to $60
12:00am, Monday, 04'th May 2020The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Traders Buy Large Volume of Put Options on NuVasive (NASDAQ:NUVA)
10:24am, Thursday, 30'th Apr 2020
NuVasive, Inc. (NASDAQ:NUVA) was the target of unusually large options trading on Tuesday. Traders bought 1,060 put options on the stock. This represents an increase of approximately 814% compared to
ARP Americas LP Trims Stock Holdings in NuVasive, Inc. (NASDAQ:NUVA)
08:36am, Thursday, 30'th Apr 2020
ARP Americas LP lowered its holdings in NuVasive, Inc. (NASDAQ:NUVA) by 37.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,694 shares of the medica
New York, April 29, 2020 -- Reportlinker.com announces the release of the report "Global Spinal Fusion Device Market - Premium Insight, Competitive News Feed Analysis, Company.
Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for
04:34pm, Wednesday, 29'th Apr 2020
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for
04:34pm, Wednesday, 29'th Apr 2020
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ra Medical Systems Appoints Joan Stafslien to its Board of Directors
10:50am, Wednesday, 29'th Apr 2020
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Joan Stafsl
Zacks: Brokerages Anticipate NuVasive, Inc. (NASDAQ:NUVA) Will Post Earnings of $0.46 Per Share
10:38am, Wednesday, 29'th Apr 2020
Wall Street brokerages expect that NuVasive, Inc. (NASDAQ:NUVA) will post earnings per share of $0.46 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for NuVasive�
NuVasive (NASDAQ:NUVA) Stock Rating Upgraded by BidaskClub
08:18am, Tuesday, 28'th Apr 2020
NuVasive (NASDAQ:NUVA) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday, BidAskClub reports. Several other research firms also recently
First Hawaiian Bank Purchases 1,152 Shares of NuVasive, Inc. (NASDAQ:NUVA)
09:14am, Saturday, 25'th Apr 2020
First Hawaiian Bank lifted its position in NuVasive, Inc. (NASDAQ:NUVA) by 17.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned
OrthoPediatrics Corp. Is Now Wildly Overvalued
05:15am, Saturday, 25'th Apr 2020
KIDS trades at over 10x 2019 revenues while comparable orthopedic companies trade at an average around 3x revenues. The company could post a decline in revenue
